Search results
Results from the WOW.Com Content Network
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Novartis is the world's first largest in life sciences and agribusiness markets. [6] It is also the second-largest pharmaceutical company by market cap in 2019. [128] Alcon: At the time Novartis bought Alcon, they had annual sales of $6.5 billion and a net income of $2 billion. [129]
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. [4] Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz.
In the Philippines, there are employers' confederations to lobby the protection of firm owners; they also represents the business sector and employers in the country. The most widely known is the Employers' Confederation of the Philippines, which is leads as the voice of the employers in labor management and socioeconomic development. [38]
Novartis has also stated that the NITD will seek to make treatments developed by the NITD available without profit to the poor in developing nations in which these diseases are endemic. [3] In 2017, NITD moved out of Singapore to be beside Novartis' infectious diseases research headquarters in Emeryville, California, United States. [4]
Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. [1] The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.
He spent eight years working in Novartis Vaccines, and was the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables. [6] [17] From 2014 to 2016, he was the Global Head of Development for Novartis Pharmaceuticals.
In response to the COVID-19 pandemic in the Philippines, proposals have been made to set up a virology research facility in the country.The Department of Science and Technology (DOST), headed by Secretary Fortunato de la Peña, announced in May 2020 that the science agency submitted a proposal to establish the Virology Institute of the Philippines, which is meant to conduct research on viruses ...